111, Inc. (YI) SEC Filings & Earnings Calls
EquiReason read 9 111, Inc. SEC filings in the last 12 months. Latest: 6-K on 2026-09-28 — 111, Inc. announces establishment of a Special Committee to evaluate a preliminary non-binding proposal and other strategic alternatives..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 25.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 15 Dec, in 52 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
28 Sep 20266-K111, Inc. announces establishment of a Special Committee to evaluate a preliminary non-binding proposal and other strategic alternatives.open
Risks flagged
Uncertainty regarding outcome of strategic review; no definitive offer or agreement yet.
“No decisions have been made with respect to the Proposal or any alternative strategic option.” · word for word
17 Sep 20266-K111, Inc. reports Q2 2026 results: revenue down 28.3% YoY due to strategic shift to asset-light model; promotional product revenue up 121% YoY; MP service revenue up 18.2% in H1; operating expenses down 16.1%; fulfillment expenses improvedearningsopen
Figures in the filing · each found in the filing text
| Fulfillment expenses as % of net revenue · Q2-2026 | 2.8% | |
| Total MP service revenue growth (H1) · Marketplace · H1-2026 | 18.2% | |
| Levofloxacin Tablets quarterly sales volume · Promotional Products · Q2-2026 | 1,041,000 | +186% y/y |
Risks flagged
Revenue decline due to strategic transition may persist; profitability uncertain.
“Net revenue decreased 28.3% YoY; company still not profitable.”
Severance costs and workforce streamlining may impact morale and operations.
“Company incurred substantial severance costs in the quarter in connection with workforce streamlining.” · word for word
17 Sep 2026SC 13DFounders and Huadeng Tech BioArray Ventures Ltd submitted a non-binding proposal to acquire all public shares of 111, Inc. at US$0.226 per share / US$4.52 per ADS in a going-private transaction.being acquiredopen
Risks flagged
Transaction completion risk
“The Proposed Transaction is subject to a number of conditions, including the negotiation and execution of definitive documents and other related agreements mutually acceptable in form and substance to the Issuer and the Consortium. Neither the Issuer nor any member of the Consortium is obligated to complete the Proposed Transaction, and a binding commitment ” · word for word
17 Sep 20266-K111, Inc. receives preliminary non-binding going-private proposal from co-founders and Huadeng Tech BioArray Ventures at $4.52/ADS, a 29.5% premium to last close.being acquiredopen
Risks flagged
Transaction may not close; subject to special committee approval and definitive agreement.
“Preliminary non-binding proposal; no binding commitment yet.”
4 Jun 20266-K111, Inc. reports Q1 2026 revenue down 33.1% YoY to RMB2.4B, net loss from continuing ops, but marketplace service revenue up 24.7% and promotional products revenue up 70.2%. Strategic transition to asset-light model.earningsopen
Figures in the filing · each found in the filing text
| Marketplace Service Revenue Growth · Q1-2026 | 24.7% | |
| Promotional Products Revenue Growth · Q1-2026 | 70.2% | |
| Fulfillment Expenses as % of Revenue · Q1-2026 | 2.6% | |
| B2B Segment Profit · B2B · Q1-2026 | $118M | -36% y/y |
| B2C Segment Profit · B2C · Q1-2026 | $8M | -15% y/y |
Risks flagged
Significant revenue decline due to strategic transition, with no guidance provided for recovery.
“Net revenue decreased 33.1% YoY; no forward guidance provided”
Net loss from continuing operations, profitability uncertain.
“Net loss from continuing operations (not explicitly quantified in excerpt but implied by negative net income)”
30 Apr 202620-F111, Inc. filed its annual report for FY2025, reporting a net loss of RMB22.5 million (US$3.2 million), an increase from the net loss of RMB20.8 million in FY2024, but a significant improvement from the net loss of RMB353.4 million in FY202earningsopen
Figures in the filing · each found in the filing text
| Cumulative capital contributions to PRC subsidiaries · FY2025 | $359M | |
| Repayments to investors in 1 Pharmacy Technology · Q1-2026 | $40M | |
| Percentage of total outstanding principal amount agreed to further restructure · Q1-2026 | 57.2% |
Risks flagged
STAR Market listing failure and redemption obligation
“As of December 31, 2025, an amount of RMB1.1 billion has been recorded under redeemable non-controlling interests and accrued expenses and other current liabilities. This amount is owed to a group of investors in 1 Pharmacy Technology pursuant to equity investments made in 2020, as previously disclosed.” · word for word
Regulatory uncertainty in China
“Uncertainties in the interpretation and enforcement of PRC laws and regulations and sudden or unexpected changes in policies, laws and regulations in China could limit the legal protections available to us.” · word for word
Historical operating losses and profitability uncertainty
“We experienced net loss in the amount of RMB353.4 million, RMB20.8 million, and RMB22.5 million (US$3.2 million) in 2023, 2024, and 2025, respectively.” · word for word
Dependence on PRC subsidiaries for dividends
“We rely on dividends and other distributions on equity paid by our subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability to conduct our business.” · word for word
Potential delisting under HFCAA
“Our ADSs may be delisted and our ADSs and Class A ordinary shares may be prohibited from trading in the over-the-counter market under the Holding Foreign Companies Accountable Act, or the HFCAA, if the PCAOB is unable to inspect or fully investigate auditors located in China for two consecutive years.” · word for word
9 Apr 20266-K111, Inc. reports Q4/FY2025 results: B2B gross margin expanded 60bps to 5.6%, achieved non-GAAP operating profitability and positive operating cash flow in both Q4 and FY2025. Revenue declined due to strategic shift to asset-light model.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q4-2025 | $2.80B | |
| B2B gross profit margin · B2B · Q4-2025 | 5.6% | |
| B2B gross profit margin · B2B · FY2025 | 5.5% |
Risks flagged
Revenue decline due to strategic divestitures and transition to asset-light model may continue to pressure top-line growth in near term
“While this structural optimization created a temporary headwind for top-line revenue” · word for word
Non-GAAP operating income decreased year-over-year in FY2025 (RMB7.7M vs RMB22.3M) reflecting intentional revenue reduction
“The year-over-year decrease reflected the intentional reduction in revenue scale resulting from the strategic transition” · word for word
17 Dec 20256-KQ3 2025 results: revenue -16.7% YoY to RMB3.0B; achieved non-GAAP net profitability; positive operating cash flow; strategic shift to asset-light model with divestitures. No guidance provided.earningsopen
Figures in the filing · each found in the filing text
| B2B Net Revenue · B2B · Q3-2025 | $2.94B | -17% y/y |
| B2C Net Revenue · B2C · Q3-2025 | $61M | -6% y/y |
| B2B Segment Profit · B2B · Q3-2025 | $167M | -14% y/y |
| B2C Segment Profit · B2C · Q3-2025 | $11M | -28% y/y |
| GMV growth from MANTIANXING initiative · Q3-2025 | 20.5% | |
| Customer count growth from MANTIANXING initiative · Q3-2025 | 31.0% |
Risks flagged
Revenue decline due to strategic divestitures and challenging macro environment.
“Net revenues decreased 16.7% YoY; management cites 'challenging macroeconomic landscape'.”
B2C segment profitability deterioration.
“B2C segment profit margin declined from 24.1% to 18.3%.”
111, Inc. — questions
- What did 111, Inc. file recently?
- 9 SEC filings in the last 12 months. Latest: 6-K on 2026-09-28 — 111, Inc. announces establishment of a Special Committee to evaluate a preliminary non-binding proposal and other strategic alternatives.
Every figure on this page comes from 111, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.